Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin lispro - Eli Lilly and Company

Next Previous
Drug Profile

Insulin lispro - Eli Lilly and Company

Alternative Names: Humalog; Humalog Junior KwikPen; Humalog N; Humalog U 200; insulin lispro injection - Eli Lilly and Company; LY 275585; LY-8888AX; Lys-B28, Pro-B29; Lyspro

Latest Information Update: 13 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetes mellitus

Most Recent Events

  • 16 Sep 2024 Eli Lilly and Company completes a clinical trial for Diabetes mellitus (Treatment-experienced) (SC, Injection) (NCT05893797)
  • 05 Oct 2023 Clinical trials in Diabetes mellitus (Treatment-experienced) in France (SC) (NCT05893797)
  • 15 Jun 2023 Eli Lilly and Company plans clinical trial for Type 1 diabetes mellitus and Type 2 diabetes mellitus (Treatment-experienced) (NCT05893797)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top